http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/author | "Roviello G.N."xsd:string |
http://purl.uniprot.org/uniprot/#_P09429-citation-24220159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/24220159 |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/pages | "347-357"xsd:string |
http://purl.uniprot.org/citations/24220159 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.pharmthera.2013.11.001"xsd:string |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/volume | "141"xsd:string |
http://purl.uniprot.org/citations/24220159 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
http://purl.uniprot.org/citations/24220159 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/24220159 |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/author | "Montesarchio D."xsd:string |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/date | "2014"xsd:gYear |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/title | "An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies."xsd:string |
http://purl.uniprot.org/uniprot/P09429 | http://purl.uniprot.org/core/citation | http://purl.uniprot.org/citations/24220159 |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/author | "Musumeci D."xsd:string |
http://purl.uniprot.org/citations/24220159 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/24220159 |
http://purl.uniprot.org/citations/24220159 | http://purl.uniprot.org/core/name | "Pharmacol. Ther."xsd:string |
http://purl.uniprot.org/uniprot/P09429#attribution-0EAC70BF56BCFE2BA2858D91127BA8CA | http://purl.uniprot.org/core/source | http://purl.uniprot.org/citations/24220159 |